Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06455969
Other study ID # STUDY23090134
Secondary ID
Status Not yet recruiting
Phase Phase 4
First received
Last updated
Start date June 17, 2024
Est. completion date August 1, 2026

Study information

Verified date June 2024
Source University of Pittsburgh
Contact Bradley C Nindl, PhD
Phone 412-246-0460
Email bnindl@pitt.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Non-combat-related muscle, tendon and bone injuries are the most common injuries suffered by military personnel, particularly in new recruits. These injuries impact military readiness and are responsible for roughly 60% of limited duty days, 65% of soldiers who are unable to deploy, and nearly $500 million in medical cost to the government annually in the Army alone. Drug interventions must be studied and developed to prevent these negative outcomes and prepare military personnel for the demands of military service. At the current time, military leadership has identified critical gaps in understanding how to minimize these injuries and train soldiers with drug intervention serving among those gaps. The goal of this study is to determine how a hormonal intervention can change muscle, tendon, and bone function as well as physical and psychological performance in response to mental and physical stress. To do so, we will examine sex hormone (testosterone, estrogen) levels, muscle, tendon, and bone images, blood samples, and physical and mental performance. We will look at things like changes in hormone levels, chemicals released from active skeletal muscles, and your body composition. The results from this study will be used to improve physical readiness training in the military with the goal of reducing injuries.


Description:

Suppression of the reproductive hypothalamic-pituitary-gonadal (HPG) axis is a common physiological response to strenuous military training and can be difficult to replicate in simulated environments. Additionally, whether HPG suppression contributes to the physiological changes, performance decrements, and high MSK injury risk associated with multi-stressor military training is unknown. Thus, we will utilize pharmacological inhibition of the HPG axis to test if estrogen and testosterone replacement will mitigate injury risk and performance decrements following military-relevant multi-stressor training. This project aims to deliver a state-of-the-art evaluation of male and female adaptive responses to multi-stressor training and evidence-based guidance for the safe and ethical use of exogenous hormone replacement as a MSK injury mitigation solution during multi-stressor training and operations.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 120
Est. completion date August 1, 2026
Est. primary completion date August 1, 2026
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: 1. Age 18-40 years 2. body mass index (BMI) 18-30 kg/m2 3. weight stable (±10 lbs) in past 2 months 4. takes part in moderate physical activity for at least 150 minutes/week 5. currently free of upper or lower body /extremity injury or impairment 6. able to commit to study duration 7. agrees to adhere to study requirements 8. not taking prescription medications or be willing to refrain from medication prior to and throughout the study period, unless approved by study physician 9. in men, total testosterone concentration within normal physiological range (300-1000 ng/dL) 10. in women, eumenorrheic (cycles of 26-35 days) and not using hormonal contraceptives for previous 3 months Exclusion Criteria: 1. Current smoker 2. current clinical diagnosis of an eating disorder 3. use of medication incompatible with measurement of reproductive and metabolic hormones or which may interfere with any of the study outcomes 4. current oligo/amenorrhea in women 5. any metabolic or endocrine disease 6. has been diagnosed with a medical condition, physical or psychological, that currently prevents potential subjects from exercising 7. currently pregnant or becomes pregnant during the study 8. history of heart condition OR high blood pressure 9. treating physician requires subject participates in medically supervised physical activity only 10. history of drug addiction, or regular use of recreational drugs 11. currently undergoing treatment for or have a history of mental health conditions 12. irregular lab results (e.g., PSA >3 ng/mL) 13. Current diagnoses of disorders known to affect bone metabolism including hyperthyroidism, hyperparathyroidism, osteomalacia, Cushing's, diabetes mellitus or renal insufficiency 14. Current use of medications known to affect bone metabolism including estrogens, androgens, anti-estrogens, bisphosphonates (oral bisphosphonates within one year of the baseline visit or IV bisphosphonates within three years of the baseline visit), calcitonin, fluoride, oral or inhaled glucocorticoids, suppressive doses of thyroxine, lithium, pharmacological doses of vitamin D (greater than 2000 IU/day), anti-convulsants, depot medroxyprogesterone within 6 months. 15. History of deep vein thrombosis, pulmonary embolism, or clotting disorders. 16. History of stroke or myocardial infarction 17. Serum 25-hydroxyvitamin D < 20 ng/mL 18. Thyroid dysfunction 19. Serum creatinine > 2 mg/dL 20. Personal history or history of a first-degree relative with breast cancer 21. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2x the upper limit of normal 22. Serum bilirubin > 2 mg/dL 23. Serum alkaline phosphatase > 150 U/L 24. Plasma hemoglobin < 10 gm/dL 25. Hematocrit > 50 26. Fracture within the last 6 months. 27. Serum testosterone level < 270 or > 1070 ng/dL 28. Systolic blood pressure > 160 or diastolic blood pressure > 95 29. Active substance abuse 30. Triglycerides > 150 fasting 31. History of hereditary angioedema 32. History of chest pain at rest, during daily activities of living, or when performing physical activity 33. Musculoskeletal injury removing subject from physical activity for more than a month within the past 2 years 34. Recreational drug use more than 2 times per month in each of the previous 6 months 35. Self-reported vision is worse than 20/20. 36. Personal history or history of a first-degree relative with breast cancer 37. Experienced a fracture within the last 6 months 38. participated and taken investigational drug in any other clinical trial (including bioequivalence study) within six months prior to study drug administration 39. Diagnosed with eating disorder 40. Have food allergies, intolerance, restriction, or special diet needs 41. History of endometriosis 42. Current diagnosis of reproductive health issues, such as ovarian cysts, PCOS, pelvic lesions, undiagnosed ovarian enlargement 43. Have undiagnosed abnormal vaginal bleeding 44. Currently breastfeeding or within 2 months after stopping breastfeeding 45. Have dietary restrictions

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Goserelin 3.6 MG
Goserelin acetate (Zoladex) is a gonadotropin-releasing hormone agonist (GnRH). GnRH agonists induce a transient increase in sex hormone concentrations, but subsequently inhibit gonadotropin secretion and the production of testosterone in men and estrogen in women. An equilibration period will occur to allow steroid concentrations to reduce.
Other:
Multi-Stressor Training
A 4-week physical training program that mimics military training.
Drug:
Testosterone gel (AndroGel 5g)
Male subjects will be randomly assigned to receive a topical testosterone gel (5g dose).
Testosterone gel (AndroGel 1.25g)
Male subjects will be randomly assigned to receive a topical testosterone gel (1.25g dose).
Estradiol / Levonorgestrel Transdermal System [Climara Pro]
Female subjects will be randomly assigned to receive a estrogen/ progesterone patch.
Placebo Patch
Female subjects will be randomly assigned to receive a placebo patch identical to the Climara Pro patch.

Locations

Country Name City State
United States Neuromuscular Research Laboratory Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Bradley Nindl U.S. Army Medical Research and Development Command

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Biomechanical: Tendon Cross-Sectional Area, change from baseline and throughout training, mean Through study completion, an average of 8 weeks
Primary Biomechanical: Tendon Shear Wave Elastography, change from baseline and throughout training, mean Through study completion, an average of 8 weeks
Primary Biomechanical: Tendon Thickness, change from baseline and throughout training, mean Through study completion, an average of 8 weeks
Primary Biomechanical: Quadriceps Muscle Cross-sectional Area, change from baseline and throughout training, mean Through study completion, an average of 8 weeks
Primary Biomechanical: Quadricpes Muscle Echointensity, change from baseline and throughout training, mean Through study completion, an average of 8 weeks
Primary Body composition: Lean mass, change from baseline, mean Through study completion, an average of 8 weeks
Primary Body Composition: Fat mass, change from baseline, mean Through study completion, an average of 8 weeks
Primary Body Composition: Body mass, change from baseline and throughout training, mean Through study completion, an average of 8 weeks
Primary Body Composition: Body Fat Percentage, change from baseline, mean Through study completion, an average of 8 weeks
Primary Biochemical: Bone turnover markers (CTx + P1NP), change from baseline, mean Through study completion, an average of 8 weeks
Primary Biochemical: Sex steroid hormones (Testosterone, Sex Hormone Binding Globulin, Estradiol), change from baseline and throughout training, mean Through study completion, an average of 8 weeks
Secondary Bone microarchitecture: High Resolution- peripheral Computed Tomography, change from baseline, mean Through study completion, an average of 8 weeks
Secondary Biochemical: Cell culture, extracellular vesicles, micro- RNAs, change from baseline and throughout study, mean Through study completion, an average of 8 weeks
Secondary Biochemical: Measures of inflammation (IL6, IL-1B, TNFa, CRP), change from baseline and throughout study, mean Through study completion, an average of 8 weeks
Secondary Biochemical: Measures of anabolism (Growth Hormone, Insulin-like growth factor-1), change from baseline and throughout study, mean Through study completion, an average of 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT03126656 - Effects of Testosterone on Myocardial Repolarization Phase 4
Terminated NCT02419105 - Effects of Transdermal Testosterone and/or Monthly Vitamin D on Fall Risk in Pre--frail Hypogonadal Seniors Phase 3
Withdrawn NCT02137265 - Assessing the Efficacy of Clomiphene Citrate in Patients With Azoospermia and Hypoandrogenism N/A
Completed NCT02233751 - Pharmacokinetic Study of Subcutaneous Testosterone Enanthate Phase 1
Completed NCT02222558 - Oral Testosterone for the Treatment of Hypogonadism in Males Phase 2
Completed NCT01887418 - Pharmacokinetic Study of Testosterone Enanthate Phase 1/Phase 2
Terminated NCT01092858 - NEBIDO in Symptomatic Late Onset Hypogonadism (SLOH) Phase 4
Completed NCT00624624 - Follow-up of Serum Androgen Profile After Bariatric Surgery in Men With Obesity Related Hypogonadotropic Hypogonadism N/A
Completed NCT00752869 - Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Phase 4
Completed NCT00613288 - Testosterone and Lipolysis, Insulin Sensitivity and Protein Metabolism N/A
Completed NCT00119483 - Older Men and Testosterone N/A
Completed NCT00838838 - Efficacy of Nebido on Bone Mineral Density (BMD) in Hypogonadal Paraplegic Patients With Confirmed Osteoporosis N/A
Completed NCT00004438 - Leuprolide in Treating Adults With Hypogonadotropism N/A
Withdrawn NCT00398034 - Analgesic Efficacy of Testosterone Replacement in Hypogonadal Opioid-treated Chronic Pain Patients: A Pilot Study. Phase 2
Completed NCT02937740 - Open-Label Study, Evaluating Patient Satisfaction and Symptom Improvement When Treating Male Hypogonadism With Natesto™ Phase 4
Completed NCT02921386 - The Effect of Various Amounts of Fat on PK of Oral Testosterone Undecanoate Phase 2
Completed NCT01717768 - Oral Testosterone for the Treatment of Hypogonadism Phase 2
Terminated NCT01460654 - Testosterone and Alendronate in Hypogonadal Men Phase 2
Completed NCT00998933 - Study of Serum Testosterone Levels in Non-dosed Females After Secondary Exposure Phase 1
Terminated NCT00743327 - Androgen Deprivation Therapy Study N/A

External Links